Anti-HIV drug development: structural features and limitations of present day drugs and future challenges in the successful HIV/AIDS treatment.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current pharmaceutical design

• Publication date

  2013-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/13816128113199990295PMID 23092282
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ritonavir

  2012cited by this paper
• Amprenavir

  2012cited by this paper
• Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.

  2010cited by this paper
• Understanding and managing the adverse effects of antiretroviral therapy.

  2010cited by this paper
• Manipulation of dendritic cell function by viruses.

  2010cited by this paper
• Novel approaches to inhibiting HIV-1 replication.

  2010cited by this paper
• Clinical management of HIV-1 resistance.

  2010cited by this paper
• Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.

  2010cited by this paper
• Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.

  2010cited by this paper
• Pharmacogenetics of antiretrovirals.

  2010cited by this paper
• HIV reservoirs, latency, and reactivation: prospects for eradication.

  2010cited by this paper
• Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.

  2009cited by this paper
• Lipids and membrane microdomains in HIV-1 replication.

  2009cited by this paper
• Virus maturation as a new HIV-1 therapeutic target

  2009cited by this paper
• The cell biology of HIV-1 virion genesis.

  2009cited by this paper
• Mechanisms employed by retroviruses to exploit host factors for translational control of a complicated proteome

  2009cited by this paper
• A Strongly Transdominant Mutation in the Human Immunodeficiency Virus Type 1 gag Gene Defines an Achilles Heel in the Virus Life Cycle

  2009cited by this paper
• The structural biology of HIV assembly.

  2008cited by this paper
• Integrase, LEDGF/p75 and HIV replication

  2008cited by this paper
• Integrase and integration: biochemical activities of HIV-1 integrase

  2008cited by this paper
• Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

  2008cited by this paper
• Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data.

  2008cited by this paper
• TRIM family proteins and their emerging roles in innate immunity

  2008cited by this paper
• Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors.

  2008cited by this paper
• Class-sparing regimens for initial treatment of HIV-1 infection.

  2008cited by this paper
• Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm

  2008cited by this paper
• Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.

  2008cited by this paper
• Novel HIV-1 reverse transcriptase inhibitors.

  2008cited by this paper
• VSV-G pseudotyping rescues HIV-1 CA mutations that impair core assembly or stability

  2008cited by this paper
• The Safety and Efficacy of Tenofovir DF in Combination with Lamivudine and Efavirenz Through 6 Years in Antiretroviral-Naïve HIV-1—Infected Patients

  2007cited by this paper
• Darunavir (TMC114): a new HIV-1 protease inhibitor

  2007cited by this paper
• Human immunodeficiency virus type 1 assembly, release, and maturation.

  2007cited by this paper
• Beyond Tsg101: the role of Alix in 'ESCRTing' HIV-1

  2007cited by this paper
• The road to chromatin — nuclear entry of retroviruses

  2007cited by this paper
• Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag.

  2007cited by this paper
• AIDS virus envelope spike structure.

  2007cited by this paper
• Transcriptional and post-transcriptional regulation of HIV-1 gene expression: role of cellular factors for Tat and Rev.

  2006cited by this paper
• Recent progress in the design of small molecule inhibitors of HIV RNase H.

  2006cited by this paper
• Rafts defined: a report on the Keystone symposium on lipid rafts and cell function Published, JLR Papers in Press, April 27, 2006.

  2006cited by this paper
• In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection

  2006cited by this paper
• Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients

  2006cited by this paper
• Integrase inhibitors to treat HIV/Aids

  2005cited by this paper
• Human Immunodeficiency Virus (HIV) Entry Inhibitors (CCR5 Specific Blockers) in Development: Are They the Next Novel Therapies?

  2005cited by this paper
• Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

  2005cited by this paper
• In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

  2005cited by this paper
• Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1

  2005cited by this paper
• Highly Potent Inhibition of Human Immunodeficiency Virus Type 1 Replication by TAK-220, an Orally Bioavailable Small-Molecule CCR5 Antagonist

  2005cited by this paper
• Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75

  2005cited by this paper
• Nucleic acid chaperone activity of HIV-1 nucleocapsid protein: critical role in reverse transcription and molecular mechanism.

  2005cited by this paper
• Tipranavir.

  2005cited by this paper
• Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.

  2004cited by this paper
• Atazanavir

  2004cited by this paper
• New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections.

  2004cited by this paper
• Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.

  2004cited by this paper
• Non‐Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present, and Future

  2004cited by this paper
• Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

  2004cited by this paper
• Fosamprenavir: advancing HIV protease inhibitor treatment options

  2004cited by this paper
• Retrovirus budding.

  2004cited by this paper
• Assembly Properties of the Human Immunodeficiency Virus Type 1 CA Protein

  2004cited by this paper
• AIDS in Africa: the impact of coinfections on the pathogenesis of HIV-1 infection.

  2004cited by this paper
• Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

  2004cited by this paper
• Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S).

  2003cited by this paper
• Toxicity of antiretroviral therapy and implications for drug development

  2003cited by this paper
• Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro

  2003cited by this paper
• Comparison of HIV‐1 and HIV‐2 infectivity from a prospective cohort study in Senegal

  2003cited by this paper
• Fitness of drug resistant HIV-1: methodology and clinical implications.

  2002cited by this paper
• Structural determinants for HIV-1 integrase inhibition by beta-diketo acids.

  2002cited by this paper
• Human immunodeficiency virus type 2.

  2002cited by this paper
• Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion.

  2002cited by this paper
• Antiretroviral-drug resistance among patients recently infected with HIV.

  2002cited by this paper
• HIV Integrase, a Brief Overview from Chemistry to Therapeutics*

  2001cited by this paper
• Plasma membrane rafts play a critical role in HIV-1 assembly and release

  2001cited by this paper
• Lopinavir‐Ritonavir: A New Protease Inhibitor

  2001cited by this paper
• Interactions among drugs for HIV and opportunistic infections.

  2001cited by this paper
• Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection.

  2000cited by this paper
• Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

  2000cited by this paper
• Antiretroviral resistance during successful therapy of HIV type 1 infection.

  2000cited by this paper
• Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients

  2000cited by this paper
• Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture.

  2000cited by this paper
• Anti-Human Immunodeficiency Virus Type 1 Activity, Intracellular Metabolism, and Pharmacokinetic Evaluation of 2′-Deoxy-3′-Oxa-4′-Thiocytidine

  1999cited by this paper
• Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells.

  1999cited by this paper
• Indinavir: a review of its use in the management of HIV infection.

  1999cited by this paper
• Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design.

  1999cited by this paper
• Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.

  1999cited by this paper
• Functions of lipid rafts in biological membranes.

  1998cited by this paper
• Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells.

  1998cited by this paper
• Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class.

  1998cited by this paper
• A new classification for HIV-1

  1998cited by this paper
• Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site.

  1998cited by this paper
• Sequential Steps in Human Immunodeficiency Virus Particle Maturation Revealed by Alterations of Individual Gag Polyprotein Cleavage Sites

  1998cited by this paper
• HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching.

  1997cited by this paper
• RNA virus mutations and fitness for survival.

  1997cited by this paper
• 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

  1997cited by this paper
• The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia.

  1997cited by this paper
• Solution structure of the N-terminal zinc binding domain of HIV-1 integrase

  1997cited by this paper
• Saquinavir: an HIV proteinase inhibitor.

  1996cited by this paper
• Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity.

  1996cited by this paper
• Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

  1996cited by this paper
• Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.

  1996cited by this paper
• An Essential Interaction between Distinct Domains of HIV-1 Integrase Mediates Assembly of the Active Multimer (*)

  1995cited by this paper

• Surfactant-based drug delivery strategies for HIV/AIDS therapy: advances in formulation and clinical translation

  2025cites this paper
• Can plant-derived anti-HIV compounds be used in COVID-19 cases?

  2022influential citation
• Photophysical Studies on Drug Conjugates of Stavudine/Zidovudine and 1,8-Naphthalimide in Different Solvent Systems

  2021cites this paper
• Design, synthesis, in vitro and in silico studies of novel 4-oxoquinoline ribonucleoside derivatives as HIV-1 reverse transcriptase inhibitors.

  2020cites this paper
• The solid-state and solution conformations of 2′-deoxy-2′-fluoro-4′-substituted nucleosides

  2020cites this paper
• Structure-activity relationship, molecular docking, and molecular dynamic studies of diterpenes from marine natural products with anti-HIV activity

  2020cites this paper
• Alkylated benzimidazoles: Design, synthesis, docking, DFT analysis, ADMET property, molecular dynamics and activity against HIV and YFV

  2020cites this paper
• Phenotypic and functional profile of IFN-α-differentiated dendritic cells (IFN-DCs) from HIV-infected individuals

  2019cites this paper
• A SCAFFOLD SIMPLIFICATION STRATEGY LEADS TO A NOVEL GENERATION OF DUAL HUMAN IMMUNODEFICIENCY VIRUS AND ENTEROVIRUS-A71 ENTRY INHIBITORS.

  2019cites this paper
• Modifications in the branched arms of a class of dual inhibitors of HIV and EV71 replication expand their antiviral spectrum

  2019cites this paper
• Molecular modeling, synthesis, antibacterial and cytotoxicity evaluation of sulfonamide derivatives of benzimidazole, indazole, benzothiazole and thiazole.

  2018cites this paper
• Human Immunodeficiency Virus Reverse Transcriptase (HIV-RT): Structural Implications for Drug Development

  2018cites this paper
• Recent 5-year Findings and Technological Advances in the Proteomic Study of HIV-associated Disorders

  2017cites this paper
• Structure‐activity relationship studies on a Trp dendrimer with dual activities against HIV and enterovirus A71. Modifications on the amino acid

  2017cites this paper
• Design and anti-HIV activity of arylsulphonamides as non-nucleoside reverse transcriptase inhibitors

  2016cites this paper
• Molecular Modeling, Synthesis, and Anti‐HIV Activity of Novel Isoindolinedione Analogues as Potent Non‐nucleoside Reverse Transcriptase Inhibitors

  2016cites this paper
• Identification and characterization of a new type of inhibitor against the human immunodeficiency virus type-1 nucleocapsid protein

  2015cites this paper
• Improving bioavailability and biodistribution of anti-HIV chemotherapy.

  2015cites this paper
• Molecular Modeling, Synthesis and Biological Evaluation of N‐Heteroaryl Compounds as Reverse Transcriptase Inhibitors Against HIV‐1

  2015cites this paper
• Tryptophan dendrimers that inhibit HIV replication, prevent virus entry and bind to the HIV envelope glycoproteins gp120 and gp41.

  2015cites this paper
• Screening and Characterization of Anti-HIV Small Molecule Inhibitors

  2014cites this paper
• Implant chargé en nanoparticules pour la libération contrôlée et le ciblage lymphatique de nucléotides et d’analogues nucléotidiques

  2014cites this paper
• Molecular dynamics modeling the synthetic and biological polymers interactions pre-studied via docking

  2014cites this paper
• The emergence of drug resistant HIV variants and novel anti-retroviral therapy.

  2013cites this paper
• The Impact of Stressful Life Events, Symptom Status, and Adherence Concerns on Quality of Life in People Living With HIV

  2013cites this paper
• Editorial: the development of novel inhibitors for the treatment of HIV infection.

  2013cites this paper